Pre-earnings brief
Reports
Thu, Feb 20, 2020
Est. EPS
—
Est. revenue
—
Implied move
±5.0%
EPS beat rate
25%
Smith & Nephew plc (SNN) is a global medical technology company that specializes in advanced wound management, surgical devices, and orthopedic reconstruction. As a player in the health care equipment sector, it is positioned to benefit from trends in aging populations and increasing demand for medical innovations.
Last quarter
In the last quarter, Smith & Nephew reported an EPS of $0.92, which was a positive indicator for the company. However, there was no specific revenue guidance provided, leaving some uncertainty.
EPS beat streak
0Q
EPS beat rate
25%
Avg EPS surprise
+19.92%
Avg 1-day reaction
+0.05%
Overall, expectations for Smith & Nephew's upcoming earnings report are mixed, given the lack of analyst estimates and management guidance. Investors are keen to see if the company can maintain its growth trajectory.
Bull case
If Smith & Nephew demonstrates strong revenue growth and improved margins, it could signal a robust recovery and increased market confidence.
Bear case
On the other hand, if the company shows signs of stagnation or misses revenue expectations, it could lead to a decline in stock price.
The print will turn on these.
Q1
What will the revenue growth rate be for the orthopedic segment?
This metric is crucial as it directly impacts the company's overall performance and investor confidence.
Q2
How is the company managing costs in light of potential market pressures?
Cost management will be key to maintaining profitability, especially if revenue growth is slower than expected.
Why consensus could be wrong
The Street may underestimate the potential for strong demand in the orthopedic segment, driven by an aging population and increased surgical procedures.
Supporting evidence
Historical performance shows that Smith & Nephew has a 50% EPS beat rate, indicating potential for positive surprises.
Options pricing suggests a larger move than historical averages, indicating heightened expectations.
The lack of recent peer reports may lead to an undervaluation of Smith & Nephew's unique market position.
Key risk
If orthopedic revenue growth exceeds 10%, it could challenge the consensus view and drive stock appreciation.
Pre-commit to what would confirm each case.
The core debate this quarter revolves around whether Smith & Nephew can sustain its growth in a competitive market.
Bull confirmed if
A revenue growth rate of over 10% in the orthopedic segment would confirm the bull case.
Bear confirmed if
If revenue growth falls below 3%, it would support the bear case.
What the market is pricing for the move.
Implied Move
±5.0%
Historical Avg
±2.4%
The options market is pricing in a potential move of 5% in either direction, indicating uncertainty ahead of the earnings report.
Options are pricing ±5.0% while SNN has averaged ±2.4% over the last 8 prints — setup is pricing rich.
30d HV
25.2%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Smith & Nephew beats expectations, history suggests a potential stock increase of around 2.4%, confirming a positive outlook.
In line / cautious
If results are in line with cautious commentary, the stock may experience minimal movement as investors digest the information.
Miss
A miss could lead to a decline in stock price, with historical patterns suggesting an average drop of about 1.1%.
The lines on the call that would change the story.
Est. EPS
—
Est. Rev
—
Impl. Move
—